Literature DB >> 15155552

A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time.

Keith W Ward1, Brian R Smith.   

Abstract

Our laboratory is engaged in an ongoing analysis of a 103-compound data set containing reliable intravenous pharmacokinetic parameters in the rat, dog, monkey, and human, and we have previously reported our findings regarding extrapolation of clearance. In this article, we report on our findings regarding volume of distribution and mean residence time. Various allometric and nonallometric methods were used to predict human volume of distribution based on preclinical pharmacokinetic data; clearance and volume of distribution values generated by various means were then used to estimate mean residence time. From both a quantitative and qualitative perspective, estimating human volume and mean residence time based on monkey data alone was the most accurate approach evaluated. For volume, estimation based on monkey data alone was quantitatively the least biased of all approaches evaluated. Additionally, prediction of mean residence time based on clearance and volume from the monkey was the only extrapolation method that exhibited a positive, rather than negative, bias. None of the allometric scaling approaches investigated afforded optimal predictivity for either volume or mean residence time, and neither the correlation coefficient nor the allometric exponent allowed a prospective estimation of predictive success or failure. These observations regarding volume and mean residence time confirm our earlier results with clearance, and further confirm the value of the monkey as a species for pharmacokinetic lead optimization.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15155552     DOI: 10.1124/dmd.32.6.612

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  21 in total

Review 1.  Applications of human pharmacokinetic prediction in first-in-human dose estimation.

Authors:  Peng Zou; Yanke Yu; Nan Zheng; Yongsheng Yang; Hayley J Paholak; Lawrence X Yu; Duxin Sun
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

2.  A novel strategy for physiologically based predictions of human pharmacokinetics.

Authors:  Hannah M Jones; Neil Parrott; Karin Jorga; Thierry Lavé
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 3.  Animal models of substance abuse and addiction: implications for science, animal welfare, and society.

Authors:  Wendy J Lynch; Katherine L Nicholson; Mario E Dance; Richard W Morgan; Patricia L Foley
Journal:  Comp Med       Date:  2010-06       Impact factor: 0.982

4.  Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates.

Authors:  Tsuyoshi Karibe; Rie Hagihara-Nakagomi; Koji Abe; Tomoki Imaoka; Tsuyoshi Mikkaichi; Satoru Yasuda; Masakazu Hirouchi; Nobuaki Watanabe; Noriko Okudaira; Takashi Izumi
Journal:  Pharm Res       Date:  2014-11-08       Impact factor: 4.200

5.  Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4).

Authors:  Carl A Brooks; Linda S Barton; David J Behm; Hilary S Eidam; Ryan M Fox; Marlys Hammond; Tram H Hoang; Dennis A Holt; Mark A Hilfiker; Brian G Lawhorn; Jaclyn R Patterson; Patrick Stoy; Theresa J Roethke; Guosen Ye; Steve Zhao; Kevin S Thorneloe; Krista B Goodman; Mui Cheung
Journal:  ACS Med Chem Lett       Date:  2019-07-15       Impact factor: 4.345

Review 6.  Comparison of Canine and Human Physiological Factors: Understanding Interspecies Differences that Impact Drug Pharmacokinetics.

Authors:  Marilyn N Martinez; Jonathan P Mochel; Sibylle Neuhoff; Devendra Pade
Journal:  AAPS J       Date:  2021-04-27       Impact factor: 4.009

7.  Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology.

Authors:  Tristan S Maurer; Avijit Ghosh; Nahor Haddish-Berhane; Aarti Sawant-Basak; Carine M Boustany-Kari; Li She; Michael T Leininger; Tong Zhu; Meera Tugnait; Xin Yang; Emi Kimoto; Vincent Mascitti; Ralph P Robinson
Journal:  AAPS J       Date:  2011-08-26       Impact factor: 4.009

Review 8.  Bisphenol A interferes with synaptic remodeling.

Authors:  Tibor Hajszan; Csaba Leranth
Journal:  Front Neuroendocrinol       Date:  2010-07-06       Impact factor: 8.606

9.  Human microdose evaluation of the novel EP1 receptor antagonist GSK269984A.

Authors:  Thor Ostenfeld; Claire Beaumont; Jonathan Bullman; Maria Beaumont; Phillip Jeffrey
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

10.  Behavioral pharmacology of the mu/delta opioid glycopeptide MMP2200 in rhesus monkeys.

Authors:  Gail Pereira Do Carmo; Robin Polt; Edward J Bilsky; Kenner C Rice; S Stevens Negus
Journal:  J Pharmacol Exp Ther       Date:  2008-05-29       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.